Beyond the Average: How Biological Sex Shapes Diagnostic Accuracy and Algorithmic Design

The Hidden Gap in Medical Diagnostics

Diagnostic accuracy is foundational to effective healthcare. Yet, for decades, medical research and clinical protocols have operated on a default model largely based on male physiology. While much attention has been directed toward clinical trial enrollment and drug metabolism, a critical diagnostic gap persists. Standardized screening tools, imaging algorithms, and laboratory reference ranges frequently underestimate pathology in women, leading to delayed diagnoses and suboptimal management. Recent evidence highlights how biological differences impact diagnostics, from artificial intelligence models analyzing medical images to laboratory equations estimating kidney function. Understanding these gaps is essential for clinicians and patients alike.

Algorithmic Blind Spots in Medical Imaging

Medical imaging has increasingly relied on machine learning and AI to improve diagnostic accuracy and workflow efficiency. However, a fundamental vulnerability exists when these models are trained on non-representative datasets. A November 2025 study published in PLoS ONE evaluated the performance of AI models in musculoskeletal ultrasound, specifically assessing joint recess distension—a key indicator of synovitis and inflammatory arthritis. The researchers found that models trained primarily on male-only data exhibited significantly reduced performance when applied to female patients. Because musculoskeletal anatomy, tissue density, and fat distribution differ between sexes, a universal algorithm can inadvertently create a systematic blind spot, potentially underestimating inflammation or structural abnormalities in women. This finding underscores a broader concern: if diagnostic AI continues to be developed without rigorous sex-stratified validation, it may perpetuate existing inequalities in rheumatology and orthopedics. While AI promises to standardize care, its reliance on historical training data means it inherits past biases unless explicitly corrected during the development phase.

Laboratory Reference Ranges and Renal Diagnosis

Beyond imaging, routine blood tests used to assess organ function may require sex-specific interpretation. Chronic kidney disease (CKD) is a condition where early detection dramatically alters long-term outcomes. Current guidelines rely heavily on estimated glomerular filtration rate (eGFR), a calculation derived largely from serum creatinine levels. Because creatinine production correlates with skeletal muscle mass, and women generally have lower muscle mass than men, standard eGFR formulas can miscalculate renal function. An October 2025 abstract presented at the annual meeting of the National Kidney Foundation highlighted gender disparities in CKD identification and nephrology referral timing. The data suggested that women with equivalent or higher degrees of underlying kidney dysfunction were sometimes diagnosed later or referred at different thresholds compared to their male counterparts. Similarly, analysis published in March 2025 in BMC Nephrology examined the real-world implementation of updated kidney failure risk equations. These studies collectively point to a nuanced problem: while updated equations attempt to address biological variance, reliance on a single standardized threshold can still mask early declines in women’s kidney health. Clinicians must remain vigilant, considering factors such as body habitus and baseline muscle mass when interpreting eGFR values, rather than treating the number as an absolute diagnostic cutoff.

In cases where eGFR falls just above traditional thresholds for intervention, yet clinical suspicion remains high due to persistent symptoms such as fatigue, swelling, or altered urinary frequency, secondary markers like cystatin C or direct imaging may offer clarifying insights. Cystatin C, a protein filtered by the kidneys that is less influenced by muscle mass, is increasingly recognized as a complementary biomarker.

Navigating Diagnostic Uncertainty and Patient Advocacy

The existence of these diagnostic gaps does not imply that current care is failing, but rather that medicine operates within the limits of population-based averages. Patients and providers can take actionable steps to mitigate these uncertainties. For individuals undergoing radiological or ultrasonographic evaluation, discussing the context of your symptoms with the interpreting clinician ensures that subtle signs are weighed alongside quantitative results. When reviewing lab work, particularly kidney function tests, asking whether results have been adjusted for baseline body composition can be a valuable conversation. Furthermore, tracking symptom progression over time often provides more reliable clinical insight than isolated data points.

The transition toward sex-aware diagnostics also carries practical challenges. Electronic health records and laboratory information systems are frequently optimized for legacy reference ranges. Updating these digital infrastructures requires institutional commitment and ongoing physician education. Moreover, while sex is a crucial biological variable, it intersects with age, genetics, and environmental exposures. Isolating sex-specific effects in diagnostic models demands robust statistical adjustment to avoid oversimplification. Recognizing these complexities prevents the creation of new rigid categories while still preserving the vital insights gained from studying biological divergence.

Bridging the Gap Through Inclusive Standards

Addressing the diagnostic gap requires sustained effort across research, clinical practice, and health technology development. Whether through retraining AI models with diverse anatomical datasets or refining laboratory equations to better reflect female physiology, the goal remains consistent: ensuring that diagnostic tools serve entire populations equitably. Patients should view current diagnostic standards as informed estimates rather than definitive answers. By maintaining awareness of how biological sex influences medical metrics, women can engage more proactively in their healthcare, and clinicians can refine their interpretive frameworks to catch what broad averages might miss. As more sex-specific data emerges, the hope is for a healthcare landscape where diagnosis is equally precise for everyone.